Status:
COMPLETED
Drug Interaction Study
Lead Sponsor:
Emalex Biosciences Inc.
Collaborating Sponsors:
Syneos Health
Cambridge Cognition Ltd
Conditions:
Drug Interaction
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a single center, 2-Part, Phase 1, open-label, fixed-sequence, drug-drug interaction study designed to compare the PK of ecopipam when administered alone and in combination with itraconazole (P...
Eligibility Criteria
Inclusion
- Male subjects or femail subjects of non-childbearing potential
- ≥18 and ≤55 years of age
- BMI \>18.5 and \<30.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.
- Subjects must be healthy, as determined by the Investigator, based on medical history, physical examination, ECG, vital signs, and standard panel of blood and laboratory tests at Screening.
- Sexually active males must use a double barrier method of contraception during the study and for at least 90 days after the last dose of study drug.
- Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.
- Willing to take off dentures or mouth piercing at the time of dosing.
Exclusion
- History of significant medical illness
- Clinically significant abnormalities on screening tests/exams
- History of or significant risk of committing suicide
- Donation of plasma within 7 days prior to dosing
- Donation or significant loss of blood within 8 weeks prior to the first dosing
- Major surgery within 3 months or minor surgery within 1 month prior to admission
- Use of prohibited prescription, over-the-counter medications or natural health products
- Female subjects who are currently pregnant or lactating
- Positive pregnancy test
- Positive urine drug screen, urine cotinine test, or alcohol breath test
- Use of tobacco or nicotine products within 1 month prior to Screening
- Significant alcohol consumption
- History of drug abuse within the previous year, or a positive drug screen
- History of allergy to study medications
- Part 1 only: Presence of orthodontic braces or orthodontic retention wires
- Recent participation in a clinical research study
- Not suitable for study in the opinion of the Principal Investigator
Key Trial Info
Start Date :
January 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 22 2024
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06194864
Start Date
January 18 2024
End Date
May 22 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Syneos Health Clinic Inc.
Québec, Quebec, Canada, G1P 0A2